Takeda Pharmaceuticals U.S.A., INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$106Mgeneral payments (2019-2025)
$10Mresearch payments (2019-2025)
156,773clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Entyvio $6.9M associated (2023-2025)
- Fruzaqla $2.4M associated (2023-2025)
- Trintellix $2.2M associated (2023-2025)
- Hyqvia $1.7M associated (2023-2025)
- Takhzyro $1.4M associated (2023-2025)
- Gattex $1.3M associated (2023-2025)
- Iclusig $1.2M associated (2023-2025)
- Alunbrig $1.1M associated (2023-2025)
- Livtencity $1.1M associated (2023-2025)
- Glassia $1.1M associated (2023-2025)
- Cuvitru $915K associated (2023-2025)
- Eohilia $778K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Keith Gottesdiener | Rahway, NJ | Infectious Disease | $1,585,573.56 |
| Michael Mendelsohn | Boston, MA | Internal Medicine | $1,521,209.86 |
| Nasser Hajaig | Phoenix, AZ | Internal Medicine | $676,586.69 |
| Franklin Charney | Denton, TX | Surgery | $511,061.85 |
| Kirk Peterson | Huxley, IA | Family Medicine | $505,034.96 |
| Thomas Scammell | Boston, MA | Neurology (Psychiatry & Neurology) | $497,162.61 |
| Kirk Dahl | Eau Claire, WI | Emergency Medicine | $484,176.50 |
| Moshe Levy | Dallas, TX | Medical Oncology | $472,082.13 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $462,892.96 |
| Gerald Dryden | Louisville, KY | Gastroenterology (Internal Medicine) | $441,620.39 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.